IGM Biosciences Inc. (IGMS)
1.24
-0.04 (-3.13%)
At close: Mar 28, 2025, 3:59 PM
1.24
0.00%
After-hours: Mar 28, 2025, 04:05 PM EDT
IGM Biosciences Income Statement
Year | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
Revenue | 2.68M | 2.13M | 1.07M | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | 8.28M | 10.6M | 7.72M | 3.58M | 2.33M | 278K | 161K |
Gross Profit | 2.68M | -6.15M | -9.53M | -7.72M | -3.58M | -2.33M | -278K | -161K |
Operating Income | -208.58M | -263.46M | -227.96M | -165.32M | -83.28M | -44.5M | -22.79M | -11.15M |
Interest Income | 12.79M | 17.74M | 7.04M | 159K | 1.93M | n/a | n/a | n/a |
Pretax Income | -195.79M | -245.74M | -221.1M | -165.16M | -81.36M | -43.13M | -22.71M | -11.05M |
Net Income | -195.79M | -246.42M | -214.25M | -160.68M | -80.33M | -42.54M | -22.71M | -11.05M |
Selling & General & Admin | 50.41M | 50.07M | 49.74M | 38.3M | 18.25M | 9.24M | 3.83M | 2.51M |
Research & Development | 160.85M | 215.52M | 179.29M | 127.03M | 65.03M | 35.26M | 18.96M | 8.64M |
Other Expenses | n/a | n/a | -181K | 159K | 1.93M | 1.36M | 80K | 93K |
Operating Expenses | 211.26M | 265.59M | 229.03M | 165.32M | 83.28M | 44.5M | 22.79M | 11.15M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 211.26M | 265.59M | 229.03M | 165.32M | 83.28M | 44.5M | 22.79M | 11.15M |
Income Tax | n/a | 678K | -6.85M | -4.48M | -1.02M | -597K | 80K | n/a |
Shares Outstanding (Basic) | 60.51M | 52.31M | 41.54M | 33.48M | 30.75M | 9M | 438.07K | 437.94K |
Shares Outstanding (Diluted) | 60.51M | 52.31M | 41.54M | 33.48M | 30.75M | 9M | 438.07K | 437.94K |
EPS (Basic) | -3.24 | -4.71 | -5.16 | -4.8 | -2.61 | -4.73 | -51.84 | -25.24 |
EPS (Diluted) | -3.24 | -4.71 | -5.16 | -4.8 | -2.61 | -4.73 | -51.84 | -25.24 |
EBITDA | -208.58M | -253.36M | -221.88M | -157.44M | -77.78M | -40.8M | -22.51M | -10.99M |
Depreciation & Amortization | n/a | 8.28M | 10.6M | 7.72M | 3.58M | 2.33M | 278K | 161K |